Earnings

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

Aptose Shareholders Approve C$2.41 Hanmi Buyout as Clinical Data Validates Triplet Strategy

By The Northwire Desk — AI Analysis Mar 31, 2026 · 17:22 APS · 2.33 APTOSE BIOSCIENCES INC.

Executive Summary

The March 31, 2026 release confirms that 91.48% of voting shareholders approved the plan of arrangement for Hanmi Pharmaceutical’s subsidiary to acquire all remaining Aptose common shares at C$2.41 per share.
The Court of King’s Bench of Alberta issued a final order approving the arrangement, with closing expected by late April 2026, subject only to customary conditions.
FY2025 unaudited financials show a net loss of $25.5M, cash of $4.1M, and negative working capital of $2.86M. R&D expenses decreased to $11.3M as the company discontinued APTO-253 and focused solely on tuspetinib.
Clinical highlights reiterate strong Phase 1/2 TUSCANY trial data: 90% CR/CRh rate for the TUS+VEN+AZA triplet, 100% response at 80mg/120mg doses, 78% MRD-negative status among responders, and no dose-limiting toxicities.

Material Impact

The news is a procedural confirmation of a transaction announced in November 2025. The market has already priced in the C$2.41 offer, leaving minimal arbitrage upside (~2.5% spread).
Financial deterioration (negative working capital, high burn rate) is rendered irrelevant for public shareholders, as Hanmi assumes funding responsibility post-closing.
The clinical data, while scientifically robust, no longer serves as a standalone equity catalyst because the company is exiting public markets. The data primarily validates Hanmi’s strategic rationale for the acquisition.
No new material information alters the investment thesis. The stock will trade in a tight range below C$2.41 until the deal closes, reflecting minor time-value and customary closing risk.

APS · Price

Company Overview

Aptose Biosciences is a clinical-stage biotechnology company focused on developing targeted therapies for acute myeloid leukemia (AML).
Flagship project: Tuspetinib (TUS), a multi-kinase inhibitor targeting FLT3, KIT, SYK, JAK, and RSK2 pathways.
Development strategy shifted exclusively to the TUSCANY Phase 1/2 trial evaluating TUS combined with venetoclax and azacitidine (VEN+AZA) as a frontline triplet therapy for newly diagnosed AML patients ineligible for intensive chemotherapy.
Secondary programs (APTO-253, luxeptinib) were discontinued to conserve capital and streamline operations ahead of the Hanmi acquisition.

More from APTOSE BIOSCIENCES INC.